Gain detailed insights into the trading activity of Congress members for Moderna on our government trades page. Stay updated on how elected officials are investing in MRNA.

Moderna - Government Trades

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Inc.

News

Downgrades

Price Target

Movers

MRNA

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here&#39;s what you need to know.

Moderna Stock Is Sliding Wednesday: Here&#39;s Why

What Did Kennedy Jr. Say On Saturday?

Government

Regulations

Health Care

Politics

Legal

General

Robert F. Kennedy, Jr. will begin Senate confirmation hearings on Wednesday as President Donald Trump&#39;s pick to lead the Department of Health and Human Services. 

Robert Kennedy Jr. Faces Senate Confirmation Hearings As Bird Flu Concerns Grow: Caroline Kennedy Says Cousin &#39;Predator&#39; Unfit For Office

iPad's Impact On Apple

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AAPL

DDOG

LPTX

TCBX

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

S&P 500 Earnings

Broad U.S. Equity ETFs

ETFs

NFLX

ORCL

The S&amp;P 500 had a strong first week, with ETFs such as SPY, VOO and IVV seeing gains. Were Trump&#39;s economic policies a factor?

3 ETFs Shine As Trump&#39;s First Week Sparks Record Gains Followed By Tech Slump

Geneva,,Switzerland,,June,15,,2023:,Who,World,Health,Organization,Headquarters

Equities

IDNA

NVAX

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald Trump&#39;s executive order to withdraw from the global health body.

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?

Stock market rally

ARKG

Tidal Trust II YieldMax MRNA Option Income Strategy ETF

MRNY

ETF Opportunities Trust T-Rex 2X Long NFLX Daily Target ETF

NFLU

NFXL

NUKZ

Global economy and financial markets saw a lot of activity in Jan. 24 week. S&amp;P 500 reached record high, several ETFs had double-digit gains.

ETFs Shine As S&amp;P 500 Hits Record High: Top 5 ETFs With Best Gains From Last Week

10 Must-Watch Shows That Are Not On Netflix

Large Cap

Tech

CIEN

GWRE

IBKR

PLTR

RKLB

SMMT

TWLO

12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts.

Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio?

Wall Street

Macro Economic Events

Forex

Econ #s

Economics

$BTC

FSLR

Wall Street hit new records as Donald Trump began his second term as 47th U.S. president this week.

Trump Sparks Records On Wall Street, AI Stargate Project Lifts Chipmakers; Inflation, Tariff Jitters Arise: This Week In The Market

Biotech

Contracts

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to enhance healthcare delivery.

Moderna Secures European Contract For Covid-19 Vaccine

Bird flu, chickens, vet

CVAC

As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop. 

Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads

Moderna Inc

Market Summary

Benzinga Market Summary: Q4 GDP Growth Misses Estimates, UPS Stock Slumps Following Q4 Results, FedEx Falls In Sympathy, Vaccine Stocks On Watch As RFK Hearings Continue, 10-Year Treasury Yield Drops

Trump Health Sec Nominee Kennedy Says He Will Support Development Of Vaccines For Bird Flu

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 31 unusual trades.
Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 17 were puts, with a value of $1,290,308, and 14 were calls, valued at $844,212.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $145.0 for Moderna, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Moderna stands at 4343.04, with a total volume reaching 15,556.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $20.0 to $145.0, throughout the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738180845_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.4</td>
<td>$4.1</td>
<td>$4.25</td>
<td>$30.00</td>
<td>$467.5K</td>
<td>4.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.3</td>
<td>$9.15</td>
<td>$9.15</td>
<td>$50.00</td>
<td>$147.3K</td>
<td>4.2K</td>
<td>161</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.6</td>
<td>$14.4</td>
<td>$14.6</td>
<td>$35.00</td>
<td>$146.0K</td>
<td>19.9K</td>
<td>152</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$44.00</td>
<td>$140.3K</td>
<td>87</td>
<td>2.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$3.55</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$44.00</td>
<td>$132.5K</td>
<td>87</td>
<td>563</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Moderna's Current Market Status</h3>
<ul>
<li>Trading volume stands at 11,242,282, with MRNA's price down by -3.65%, positioned at $43.3.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 16 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $66.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Moderna, which currently sits at a price target of $38. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Moderna, which currently sits at a price target of $96. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Moderna with a target price of $99. 
&#x2A; In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral, setting a price target of $51. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Moderna, targeting a price of $50. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Decoding Moderna's Options Activity: What's the Big Picture?

<a href="https://www.youtube.com/watch?v=e040JFe7bK0">https://www.youtube.com/watch?v=e040JFe7bK0</a>
&nbsp;

Trump Health Sec Nominee Kennedy Says He Will Not Pause Research On Bird Flu; Says He Will "Devote The Appropriate Resources To Preventing Pandemics" With Respect To Bird Flu

Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here&#8217;s what <a href="https://www.benzinga.com/pressreleases/25/01/ac43298267/moderna-to-report-fourth-quarter-and-full-year-2024-financial-results-on-friday-february-14-2025">you need to know</a>.
What To Know: Goldman Sachs analyst Salveen Richter downgraded Moderna from <a href="https://www.benzinga.com/analyst-stock-ratings">Buy to Neutral</a> on Wednesday and lowered the price target from&nbsp;$99&nbsp;to&nbsp;$51, citing lower conviction following another product revenue guidance adjustment. 
Moderna&#8217;s most recent product revenue guidance is the second downward revision over the past six months, according to Richter. 
&#8220;Which while potentially at an achievable level, leads us to believe MRNA has limited visibility on the revenue stream for the respiratory vaccine business,&#8221; the analyst said. 
Richter now expects Moderna to report product revenue at the low end of its guidance range of $1.5 billion to $2.5 billion. The analyst cited several reasons for his cautiousness including potential additional competitive pressure in the COVID vaccine market, a potential reduction in vaccination rates and uncertainty around re-vaccination recommendations. 
The Goldman analyst also adjusted his forecasted probability of success for multiple vaccines including the company&#8217;s cytomegalovirus (CMV) vaccine, which did not meet the criteria for early efficacy in a Phase 3 trial. The study is continuing and Moderna anticipates final efficacy data later this year. 
See Also: <a href="https://www.benzinga.com/news/earnings/25/01/43303023/teva-pharmaceutical-stock-falls-on-q4-earnings-whats-going-on">Teva Pharmaceutical Stock Falls On Q4 Earnings: What&#8217;s Going On?</a>
Richter lowered the probability of success for the company&#8217;s CMV vaccine from 90% to 80%. The analyst also lowered the probability of success for the company&#8217;s EBV vaccine from 85% to 70%. 
The firm&#8217;s 12-month price target is based on a 100% discounted cash flow value of $51. 
Moderna on Wednesday scheduled its<a href="https://www.benzinga.com/calendars/earnings"> fourth-quarter financial results</a> for Feb. 14. Analysts currently expect the company to report a loss of $2.75 per share and revenue of $986.03 million, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
MRNA Price Action: <a href="http://benzinga.com/quote/mrna">Moderna shares</a> were down 8.21% at $41.25 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Moderna Stock Is Sliding Wednesday: Here's Why

<a href="https://www.youtube.com/watch?v=e040JFe7bK0" title="https://www.youtube.com/watch?v=e040JFe7bK0">https://www.youtube.com/watch?v=e040JFe7bK0</a>

BNTX

Trump Health Sec Nominee Kennedy Appears In Front Of U.S. Senate Finance Committee For Nomination Hearing; Says He Promised Trump That If Confirmed Will Do Everything Possible To Put Health Of Americans Back On Track

Robert F. Kennedy, Jr. will begin Senate confirmation hearings on Wednesday as President Donald Trump's pick to lead the Department of<a href="https://www.benzinga.com/general/health-care/25/01/43257413/trumps-executive-order-leads-to-cdc-halting-collaboration-with-who-amid-h5n9-bird-flu-discovery-and-rfk-jrs-senate-hearings"> Health and Human Services.&nbsp;</a>
What To Know: If confirmed by the Senate, Kennedy would oversee the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, Medicare and Medicaid as the secretary of the Department of Health and Human Services.&nbsp;
Kennedy is set to appear before the Senate Committee on Finance on Wednesday where he is expected to face questions regarding his unorthodox views on vaccines, abortion and "Make America Healthy Again&#8221; agenda. He will stand before the Senate Committee on Health, Education, Labor and Pensions on Thursday, where he&#8217;s likely to face similar questions. 
Read Next: <a href="https://www.benzinga.com/government/regulations/25/01/43292056/judge-blocks-trumps-order-to-freeze-federal-grant-money">Judge Blocks Trump&#8217;s Order To Freeze Federal Grant Money</a>&nbsp;
Senators are likely to question Kennedy's views on <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">vaccine research</a> as the nominee has supported debunked theories that certain routine childhood vaccines cause autism. He was also an outspoken critic of COVID-19 vaccines produced by Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>). 
Questions on Kennedy's skepticism of vaccines is timely as bird flu is spreading through wild birds and poultry farms in the U.S.. A new strain of bird flu was identified at a duck farm in California and is raising concerns that the virus is mutating in a way that could create a wider outbreak in humans, according to<a href="https://www.washingtonpost.com/health/2025/01/28/new-bird-flu-strain-h5n9-california/"> a report</a> from the Washington Post.&nbsp;
While campaigning for president in 2024, Kennedy <a href="https://x.com/RobertKennedyJr/status/1804923391595696553">wrote a post</a> on social media doubting the safety and efficacy of bird flu vaccines in particular. 
"There is no evidence these vaccines will work, and they appear to be dangerous," Kennedy wrote.&nbsp;
He also attempted to push a conspiracy theory where deadly bird flu strains were being engineered in government labs in order to create a market for pharmaceutical companies to profit from vaccines. 
"We already know our public health agencies are out of control.&nbsp; We have to stop the runaway gain-of-function experiments and the highly lucrative pandemic vaccine experiments right now," he wrote.&nbsp;
What Else: A member of the Kennedy family, Caroline Kennedy, released <a href="https://static01.nyt.com/newsgraphics/documenttools/43900493f7c3ca36/abcd0d91-full.pdf">a letter </a>on Tuesday urging members of the Senate to reject the nomination of her cousin as secretary of health.&nbsp;
In the letter, Caroline Kennedy described Robert Kennedy as a drug addict and a charismatic predator. She alleged he "enjoyed" placing baby chicks and mice in a blender to feed to his birds in a "perverse scene of despair and violence." 
Caroline is the former U.S. ambassador to Australia and Japan and the daughter of former President John F. Kennedy. Her cousin Robert is the son of Robert F. Kennedy, the former presidential candidate, attorney general and senator. Both men were assassinated in the 1960s. 
She praised the American health care system as the best in the world in her statement and said the American people deserve a better leader for the country&#8217;s critical health systems. 
"They deserve a Secretary committed to advancing cutting-edge medicine to save lives, not rejecting the advances we have already made. They deserve a stable, moral, and ethical person at the helm of this crucial agency. They deserve better than Bobby Kennedy- and so do the rest of us," Kennedy wrote. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a></li>
</ul>
Image: Shutterstock.

Robert Kennedy Jr. Faces Senate Confirmation Hearings As Bird Flu Concerns Grow: Caroline Kennedy Says Cousin 'Predator' Unfit For Office

ASML

NVDA

QRVO

TMUS

Benzinga Market Summary: S&P Slips Ahead Of Fed Decision, RFK Jr. Confirmation Hearings To Begin Today, T-Mobile Surges On Earnings Beat, Chip Stocks Are Mixed At Open

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Oppenheimer analyst Martin Yang downgraded the rating for Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Outperform to Perform. Apple shares closed at $238.26 on Tuesday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Salveen Richter downgraded Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from Buy to Neutral and lowered the price target from $99 to $51. Moderna shares closed at $44.94 on Tuesday. <a href="https://www.benzinga.com/quote/MRNA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Wood Lay downgraded the rating for Third Coast Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) from Outperform to Market Perform but raised the price target from $40 to $42. Third Coast Bancshares shares closed at $37.05 on Tuesday. <a href="https://www.benzinga.com/quote/TCBX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Swayampakula Ramakanth downgraded Leap Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) from Buy to Neutral. Leap Therapeutics shares closed at $0.65 on Tuesday. <a href="https://www.benzinga.com/quote/LPTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Brad Reback downgraded the rating for Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from Buy to Hold and lowered the price target from $165 to $140. Datadog shares closed at $151.89 on Tuesday. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/29085941/image-233-1024x583.png" alt="" class="wp-image-755859" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/29085941/image-233-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/29085941/image-233-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/29085941/image-233-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/29085941/image-233.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43301090/how-to-earn-500-a-month-from-meta-platforms-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Meta Platforms Stock Ahead Of Q4 Earnings</a></li>
</ul>

WIIM

Moderna shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral and lowered its price target from $99 to $51.

Goldman Sachs analyst Salveen Richter downgrades Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from Buy to Neutral and lowers the price target from $99 to $51.

Goldman Sachs Downgrades Moderna to Neutral, Lowers Price Target to $51

Donald Trump's first week in the Oval Office proved to be a blockbuster one for the markets. The S&amp;P 500 surged 1.7%, delivering its best first-week performance under a new presidency since Ronald Reagan <a href="https://www.benzinga.com/25/01/43122112/us-stocks-likely-to-open-higher-as-president-trump-announces-500-billion-ai-project-oracle-netflix-nvidia-among-stocks-in-focus">took office in 1985</a>.
On Monday, Jan. 27, <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43244872/tech-stocks-tumble-on-ai-nightmare-nvidia-eyes-worst-day-since-march-2020-bitcoin-drops-below-100000-whats-driving-markets-monday">tech stocks plummeted</a>. On Tuesday, Wall Street <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43283732/tech-rebounds-after-black-monday-nvidia-rallies-6-gm-plummets-whats-driving-markets-tuesday">attempted a rebound</a>.
Whether this market trajectory will deplete or restore optimism around the corporate earnings season remains to be seen. In the meantime, here&#8217;s a look at three exchange-traded funds that <a href="https://www.benzinga.com/etfs">mirror the S&amp;P 500 Index</a>.
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) holds 504 stocks across multiple sectors, including information technology, financials, consumer discretionary, and health care. With an AUM of $549.97 billion, SPY charges 0.09% in annual expense fees.</li>
<li>The Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>), which comes with an expense ratio of a meager 0.02%, holds 505 stocks, and manages assets worth $472 billion.</li>
<li>iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>), another popular choice, offers similar sector allocations and has an expense ratio of 0.03%.</li>
<li>Both VOO and IVV saw gains in line with SPY, as their diversified portfolios factored in the week's broader market rally.</li>
</ul>
<h1 class="wp-block-heading">What Moved The Markets?</h1>
Investors welcomed <a href="https://www.benzinga.com/markets/25/01/43219264/trumps-tariff-plans-ignite-market-rally-pushing-stocks-to-record-highs">Trump's proposal to cut the corporate tax rate</a> from 21% to 15%, expecting the move would drive business growth and investment within the U.S.
Trump also proposed raising taxes on businesses outside of the U.S., a move he said could bring "<a href="https://www.benzinga.com/news/global/25/01/43170854/trump-outlines-economic-reset-at-davos-5-things-you-need-to-know">hundreds of billions, even trillions" of dollars</a> into the economy and boost domestic manufacturing and job creation. Trump also focused on energy, urging OPEC to boost production and lower prices, while signing executive orders to expand U.S. oil and gas production. 
The <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43135764/trumps-500-billion-stargate-ai-plan-puts-3-etfs-in-focus">Stargate AI Infrastructure Project </a>was also introduced, which, backed by OpenAI, SoftBank and Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), plans to invest up to $500 billion in building AI infrastructure across the U.S., with an initial commitment of $100 billion. This project has the potential to create 100,000 jobs, Trump said.
A strong start to the corporate earnings season also played a big role in the rally.
But on Monday, U.S. tech stocks plunged as word spread of China&#8217;s DeepSeek R1, <a href="https://www.benzinga.com/25/01/43232316/deepseek-jitters-shatter-us-tech-stocks-wipe-out-12-trillion-on-wall-street-analyst-eyes-four-chinese-giants-set-to-benefit">shaking investor confidence</a>.
<h1 class="wp-block-heading">The Stocks That Powered The ETFs</h1>
The ETFs saw gains across various sectors, but a handful of stocks stood out as top performers:
<ul>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>): The pharmaceutical giant gained 21.6% last week, buoyed by its innovations in mRNA-based therapies.</li>
<li>Oracle: A key partner in the Stargate AI project, Oracle rose 14%.</li>
<li>Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>): The streaming stalwart also jumped 14% on strong results and upward revision in guidance.</li>
<li>Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>): The energy company climbed 11.8%, benefiting from bullish sentiments in the energy sector.</li>
<li>Amphenol Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>): Known for its high-tech interconnect systems, Amphenol rose 11.2%, boosted by a positive earnings revision.</li>
</ul>
See Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43253190/deepseek-ai-etfs-take-a-hard-hit-amid">DeepSeek AI Model Sends Shockwaves Through Nvidia, Slams ETFs</a></li>
</ul>
Photo: Shutterstock.

3 ETFs Shine As Trump's First Week Sparks Record Gains Followed By Tech Slump

Moderna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NYSE">MRNA</a>) short percent of float has risen 13.6% since its last report. The company recently reported that it has 43.01 million shares sold short, which is 14.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Moderna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738093510_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Moderna has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Moderna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Moderna's peer group average for short interest as a percentage of float is 4.85%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Moderna?

Shares of vaccine stocks are trading higher. HHS Secretary nominee Robert F. Kennedy Jr. reportedly said he is not anti-vaccine ahead of upcoming confirmation hearings.

<a href="https://www.bloomberg.com/news/articles/2025-01-28/rfk-jr-says-he-s-not-anti-vaccine-sees-critical-role-for-shots?srnd=homepage-asia" title="https://www.bloomberg.com/news/articles/2025-01-28/rfk-jr-says-he-s-not-anti-vaccine-sees-critical-role-for-shots?srnd=homepage-asia">https://www.bloomberg.com/news/articles/2025-01-28/rfk-jr-says-he-s-not-anti-vaccine-sees-critical-role-for-shots?srnd=homepage-asia</a>

"RFK Jr. Says He's Not Anti-Vaccine, Sees Critical Role for Shots" - Bloomberg News

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Buy and lowers the price target from $112 to $99.

Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $99

Global health concerns escalated Monday as the U.S. Centers for Disease Control and Prevention reportedly halted collaboration with the World Health Organization, coinciding with the discovery of a rare H5N9 bird flu strain in California and upcoming Senate confirmation hearings for vaccine skeptic Robert F. Kennedy Jr.
What Happened: The developments sent ripples through healthcare stocks, with vaccine manufacturers showing mixed reactions. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) edged up 0.58%, while Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) gained 2.95% amid heightened focus on potential bird flu preparedness.
CDC official John Nkengasong&#8216;s Sunday memo, <a href="https://apnews.com/article/cdc-who-trump-548cf18b1c409c7d22e17311ccdfe1f6">viewed</a> by The Associated Press, ordered an immediate stop to all WHO collaborations, catching health experts off guard as the U.S. faces multiple health challenges, including 13 measles outbreaks this year.
The first U.S. H5N9 outbreak, detected at a Merced County duck farm alongside the more common H5N1 strain, led to the culling of 119,000 birds, Reuters reported.
The discovery comes as egg prices nationwide hit $4.15 per dozen in December. The United States Department of Agriculture is projecting a further 20% increase this year due to ongoing bird flu impacts, according to a separate Associated Press <a href="https://apnews.com/article/egg-prices-bird-flu-poultry-inflation-9ea9934e20e3fe393abb1bb85aa31c30">report</a>.
The timing is particularly significant as Kennedy, known for his vaccine skepticism, faces Senate confirmation hearings this week for Health and Human Services Secretary. His potential appointment has already influenced market sentiment, with some vaccine stocks experiencing volatility.
&#8220;The concurrent WHO separation and emerging health threats create significant uncertainty for healthcare investors,&#8221; said Dr. Jeffrey Klausner, a University of Southern California public health expert.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43256425/nvidia-says-deepseek-an-illustration-of-how-new-ai-models-can-be-created-while-being-export-control-compliant-amid-600-billion-market-value-plunge">Nvidia Says DeepSeek An &#8216;Illustration&#8217; Of How New AI Models Can Be Created While Being Export-Control Compliant Amid $600 Billion Market Value Plunge</a>
Why It Matters: The healthcare sector&#8217;s response reflects broader market concerns. The iShares Genomics Immunology and Healthcare ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NASDAQ">IDNA</a>) has gained 1.2% year-to-date, while <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">major vaccine producers</a> maintain substantial government contracts for flu preparedness.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), GlaxoSmithKline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), and other manufacturers secured $72 million in federal funding last October for bird flu vaccine production. Moderna separately received $176 million from BARDA for mRNA-based H5N1 vaccine development.
The CDC decision follows President Donald Trump&#8216;s executive order to withdraw from WHO, though the complete withdrawal requires congressional <a href="https://www.benzinga.com/25/01/43125408/trump-signs-order-to-withdraw-us-from-who-again-cites-funding-governance-concerns">approval and a one-year notice period</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43256454/bitcoin-ethereum-dogecoin-recover-as-deepseek-troubles-mount-for-us-tech-stocks-analyst-suggests-btc-could-hit-fresh-highs-over-upcoming-two-weeks">Bitcoin, Ethereum, Dogecoin Recover As DeepSeek Troubles Mount For US Tech Stocks: Analyst Suggests BTC Could Hit Fresh Highs Over Upcoming Two Weeks</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

A lot happened in the global economy and financial markets, the week ended Jan. 24. Major U.S. stock indexes extended their gains for a second straight week. The S&amp;P 500 reached a record high as strong corporate earnings and economic data buoyed investor sentiment. 
During these events, <a href="https://www.benzinga.com/etfs">several ETFs stood out</a> for their solid performance, with notable gains across sectors such as technology, energy, and fixed income. Let us delve into the key market trends of the week in this recap and identify five ETFs that posted double-digit gains during this period:
<h1 class="wp-block-heading">T-Rex 2X Long NFLX Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/NFLU#BATS">NFLU</a>)</h1>
Weekly gain: 35.18%
Focus: Provides 2x leveraged exposure to the daily price movements of Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)
Expense ratio: 1.05%
<h1 class="wp-block-heading">ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)</h1>
Weekly Gain: 12.32%
Focus: Allocates at least 80% of its assets to equity of companies across healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the genomics revolution theme. 
Expense Ratio: 0.75%
<h1 class="wp-block-heading">Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>)</h1>
Weekly Gain: 10.73%
Focus: Tracks the S-Network Space Index and has holdings in companies that post at least 50% of their revenues or profits from space-related businesses.
Expense Ratio: 0.85%
<h1 class="wp-block-heading">Range Nuclear Renaissance Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUKZ#NYSE">NUKZ</a>)</h1>
Weekly Gain: 11.3%
Focus: Mirrors the Range Nuclear Renaissance Index and has holdings in companies like Cameco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), Constellation Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) and Nuscale Power Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>). JP Hitachi Ltd
Expense Ratio: 0.85%
<h1 class="wp-block-heading">YieldMax MRNA Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNY#NYSE">MRNY</a>)</h1>
Weekly Gain: 12.68%
Focus: Mirrors the S&amp;P SmallCap 600 Index and seeks current income while maintaining the opportunity for exposure to the share price of Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)
Expense Ratio: 0.99%
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43201014/stocks-stall-gold-nears-record-highs-as-dollar-faces-worst-week-since-july-2023-whats-driving-markets-friday">Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What&#8217;s Driving Markets Friday?</a>
<h1 class="wp-block-heading">What Drove The Markets</h1>
Major U.S. stock indexes rose for the second week straight, driven by a rally on Thursday that sent the S&amp;P 500 to a new record high, surpassing the mark set seven weeks earlier. The Dow Jones Industrial Average and the NASDAQ both posted weekly gains of about 2%, though they remain around 1% below their records from last month.
Fourth-quarter earnings projections improved slightly. Net income for S&amp;P 500 companies is expected to grow by 12.7% year-over-year, according to FactSet. This will mean the highest quarterly earnings growth rate in three years, based on reported results and predictions.
U.S. consumer sentiment declined in January for the first time in six months, as indicated by a University of Michigan survey. Major concerns among respondents were about rising inflation and unemployment.
U.S. crude oil prices slipped more than 3% this week, ending a four-week streak gains. Oil traded around $74 per barrel on Friday, down from a peak above $80 on Jan. 15. Yet, year-to-date oil prices remain around 5% up.
Taking advantage of the dollar&#8217;s weakness and rising disagreements between the president and the central bank, gold rallied, closing in on all-time highs.
See Next: • <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43244039/ironhold-capital-cio-reveals-trends-hedge-funds-track-4-etfs-to-watch">IronHold Capital CIO Reveals Trends Hedge Funds Track: 4 ETFs To Watch</a>
Photo: Shutterstock

ETFs Shine As S&P 500 Hits Record High: Top 5 ETFs With Best Gains From Last Week

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

AEMD

APDN

CMRX

GOVX

TNXP

VRAX

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a In-Line and lowers the price target from $60 to $50.

Evercore ISI Group Maintains In-Line on Moderna, Lowers Price Target to $50

Press Releases

Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Moderna Announces Updates on Pandemic Influenza Program

Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union

Earnings

Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025

Small Cap

Opinion

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

Bird Flu Leads To Egg Shortages And Price Rise In America

AVAI

FHTX

GEHC

OMGA

SANA

TDOC

Goldman Sachs

Evercore ISI Group

Morgan Stanley

B of A Securities

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology


Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale	Mar 07, 2024	Feb 01, 2024	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale	Oct 15, 2023	Sep 15, 2023	House
Daniel GoldmanHouse (D-NY)	$50K - $100K	stock	Sale	Aug 13, 2023	Jul 12, 2023	House
Daniel GoldmanHouse (D-NY)	$50K - $100K	stock	Purchase	May 19, 2023	Apr 10, 2023	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Purchase	Apr 20, 2023	Mar 31, 2023	House
Daniel GoldmanHouse (D-NY)	$50K - $100K	stock	Sale	Apr 17, 2023	Mar 06, 2023	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale	Apr 17, 2022	Mar 16, 2022	House

Government Trades

Moderna Inc

top performing MRNA trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga